Heart Failure
Digital health app may improve self-care after acute HF hospitalization
Compared with the usual care alone, a mobile app intervention plus the usual care may improve HF quality of care by improving patients’ own self-care after hospitalization for acute HF, a speaker reported.
EMPEROR-Preserved: Empagliflozin reduces risk for serious hospitalizations in HFpEF
In patients with HF with preserved ejection fraction, empagliflozin reduced risk for serious hospitalizations compared with placebo, according to new data from the EMPEROR-Preserved trial.
Longer duration diabetes, prediabetes increase heart failure risk
Diabetes duration, including prediabetes, is independently associated with risk for incident heart failure, with greater risks for women and Black adults, according to data presented at the Heart in Diabetes CME Conference.
Longer duration diabetes, prediabetes increase heart failure risk
Diabetes duration, including prediabetes, is independently associated with risk for incident heart failure, with greater risks for women and Black adults, according to data presented at the Heart in Diabetes CME Conference.
Anti-arrhythmic effects of SGLT2 inhibitors 'may be an alias for improving heart failure'
SGLT2 inhibitors may directly or indirectly impact factors associated with diabetes and atrial fibrillation/atrial flutter, according to a speaker at the Heart in Diabetes CME Conference.
SARS-CoV-2 has multifaceted CV involvement, unlike previous coronaviruses
In contrast to previous coronaviruses, SARS-CoV-2, the virus causing COVID-19, produces many CV consequences, according to a presentation at the Heart in Diabetes CME Conference.
FDA grants breakthrough therapy designation to empagliflozin for HFpEF
The FDA granted breakthrough therapy designation for empagliflozin as an investigational treatment for adults with HF with preserved ejection fraction, Boehringer Ingelheim and Eli Lilly reported.
New, worsening HF most common causes of type 2 MI
New and worsening chronic HF were the most common causes of type 2 MI, and 20% of patients with a type 2 MI event were readmitted for HF within 1 year, according to data published in the Journal of the American Heart Association.
Ablation plus CRT superior to drug therapy in patients with permanent AF, narrow QRS
Rate control with AV junction ablation plus biventricular pacing improved survival among patients with permanent atrial fibrillation, narrow QRS and a prior HF hospitalization compared with medical rate control therapy, a speaker reported.
Finerenone shows HF benefit in mild to moderate diabetic kidney disease: FIGARO-DKD
The nonsteroidal mineralocorticoid receptor antagonist finerenone reduced CV event risk by 13% for adults with diabetic kidney disease compared with placebo, primarily driven by a 29% reduction in HF hospitalizations.